Reports Q2 revenue $9.2B, consensus $8.91B. “We’re delivering strong performance and reaching more patients with innovative medicines and biosimilars that address serious diseases. We continue to invest in science that enables longer, healthier lives and supports sustainable, long-term growth,” said Robert Bradway, chairman and chief executive officer.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Notable companies reporting after market close
- Is AMGN a Buy, Before Earnings?
- Amgen’s Promising Phase 3 Study on Weight Loss Drug Maridebart Cafraglutide
- Amgen’s Tarlatamab Study: A Potential Game-Changer in Lung Cancer Treatment
- Amgen’s AMG 193 Study: A Potential Game-Changer in Thoracic Tumor Treatment